LBRX

LB Pharmaceuticals Inc

Jun 05 • 04:00PM ET

28.53

-0.37 -1.28 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: KYMR RYTM INCY NUVL BMRN VKTX KRYS AXSM MDGL NBIX

| Held by: VTI IWM VXF SCHA VTWO XPH IWO IWN IHE IWC

Index	RUT	P/E	-	EPS (ttm)	-1.49	Insider Own	27.59%	Shs Outstand	28.67M	Perf Week	2.00%
Market Cap	818.14M	Forward P/E	-	EPS next Y	-4.39	Insider Trans	0.00%	Shs Float	20.76M	Perf Month	-10.84%
Enterprise Value	455.97M	PEG	-	EPS next Q	-0.82	Inst Own	87.14%	Short Float	19.36%	Perf Quarter	19.97%
Income	-38.95M	P/S	-	EPS this Y	-12.55%	Inst Trans	6.40%	Short Ratio	17.09	Perf Half Y	52.08%
Sales	0.00M	P/B	2.16	EPS next Y	-24.49%	ROA	-14.55%	Short Interest	4.02M	Perf YTD	28.17%
Book/sh	13.21	P/C	2.24	EPS next 5Y	-9.62%	ROE	-15.70%	52W High	33.47 -14.76%	Perf Year	-
Cash/sh	12.75	P/FCF	-	EPS past 3/5Y	-15.94% -	ROIC	-10.21%	52W Low	13.36 113.55%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.12% 5.83%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	35.45%	Oper. Margin	-	ATR (14)	1.69	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	35.68	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.51	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	35.68	EPS Q/Q	-221.75%	SMA20	-1.69%	Beta	-	Target Price	45.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-0.82%	Rel Volume	0.67	Prev Close	28.90
Employees	27	LT Debt/Eq	0.01	Earnings	May 12 AMC	SMA200	29.08%	Avg Volume	235.11K	Price	28.53
IPO	Sep 11, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.07% -	Trades		Volume	156,848	Change	-1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-26	Initiated	H.C. Wainwright	Buy	$45
Apr-10-26	Initiated	Craig Hallum	Buy	$36
Jan-09-26	Initiated	Roth Capital	Buy
Oct-06-25	Initiated	Stifel	Buy	$27
Oct-06-25	Initiated	Piper Sandler	Overweight	$78
Oct-06-25	Initiated	Leerink Partners	Outperform	$34

May-28-26 04:05PM	LB Pharmaceuticals to Participate in Upcoming June Investor Events (GlobeNewswire)
May-12-26 04:15PM	LB Pharmaceuticals Inc.: Q1 Earnings Snapshot (Associated Press)
04:05PM	LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-22-26 04:05PM	LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia (GlobeNewswire)
Apr-09-26 04:05PM	LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.42%
12:00PM	Loading…
Mar-27-26 12:00PM	LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) (GlobeNewswire)
Mar-26-26 04:21PM	LB Pharmaceuticals Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-25-26 08:00AM	LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia (GlobeNewswire)
Mar-09-26 08:00AM	LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors (GlobeNewswire)
Mar-04-26 04:05PM	LB Pharmaceuticals to Participate in Upcoming March Investor Events (GlobeNewswire)
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
Feb-10-26 04:41PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-26 08:00AM	LB Pharmaceuticals Announces $100.0 Million Private Placement (GlobeNewswire) +12.71%
Jan-27-26 08:06AM	LB Pharmaceuticals initiates Phase 2 trial of LB-102 (TipRanks)
08:00AM	Loading…
Jan-26-26 08:00AM	LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program (GlobeNewswire) -6.40%
Jan-21-26 08:00AM	LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel (GlobeNewswire)
Jan-12-26 04:05PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
Jan-06-26 07:00AM	LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture (GlobeNewswire)
Dec-10-25 05:04PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.29%
Dec-09-25 08:00AM	LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices (GlobeNewswire)
Nov-24-25 08:00AM	LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) +5.28%
Nov-12-25 04:15PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.63%
08:00AM	LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire)
Nov-06-25 04:05PM	LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference (GlobeNewswire)
08:12AM	LB Pharmaceuticals Inc.: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-25 08:30AM	LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs (GlobeNewswire)
Oct-06-25 08:30AM	LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms (GlobeNewswire)
Sep-25-25 08:30AM	LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani (GlobeNewswire)
04:27PM	Loading…
Sep-12-25 04:27PM	Crunching the numbers on this week's IPO performances (Yahoo Finance Video)

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

J.D.Ms. Heather D. Turner Esq.

Chief Operating & Business OfficerMr. Gad Soffer

Chief Medical OfficerDr. Anna Eramo M.D.

Senior Vice President of FinanceMr. Marc L. Panoff CPA

Ph.D.Ms. Minako Pazdera J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Deep Track Biotechnology Maste	10% Owner	Sep 12 '25	Buy	15.00	2,000,000	30,000,000	2,686,138	Sep 16 06:09 PM
Deep Track Biotechnology Maste	10% Owner	Sep 12 '25	Buy	15.00	666,666	9,999,990	666,666	Sep 16 06:09 PM
Pontifax Management 4 G.P. (20	10% Owner	Sep 12 '25	Buy	15.00	1,000,000	15,000,000	1,411,681	Sep 16 04:15 PM
Nussbaum Ran	Director	Sep 12 '25	Buy	15.00	1,000,000	15,000,000	1,411,681	Sep 16 04:15 PM
Vida Ventures GP III, L.L.C.	10% Owner	Sep 12 '25	Buy	15.00	333,333	4,999,995	880,214	Sep 16 03:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LBRX

LB Pharmaceuticals Inc

Upgrade your Finviz experience